Skip to main content

Advertisement

Table 1 Laboratory investigation before and after three years of combined conventional and GH replacement therapy

From: Effect of growth hormone replacement therapy in a boy with Dent's disease: a case report

  24mo pre-GH Baseline 24 mo post-GH 36mo post-GH
  Hydrochlorothiazide Hydrochlorothiazide + phosphate
+ K-citrate
+calcitriol+rhGH
Hydrochlorothiazide + phosphate
+K-citrate +calcitriol+rhGH
Hydrochlorothiazide + phosphate
+K-citrate
+calcitriol+rhGH
> 2 GH peaks at night
(nl > 20 mU/L)
22.0-28.0 nd nd nd
GH peaks with provocative stimuli (nl > 20 mU/L) nd nd nd 33
(2 mo without GH therapy)
IGF-1
(9 y: nl 123-275 ng/ml)
(11 y: 139-395 ng/ml)
(12 y: 143-693 ng/ml)
nd 122
(before GH therapy)
300.5 - 496
(with GH therapy)
90-125
(2 mo without GH therapy)
Calcium (s)
(nl 2.1-2.5 mmol/L)
2.4 2.4 2.4 2.3
Phosphate (s)
(nl 0.8-1.5 mmol/L)
1.0 0.74 0.96 1-1.25
iPTH
(nl 0.95-5.7 pmol/l)
n.d 6.1 n.d 2.68
ALP (5-10 yr: 110-341 U/L)
(Puberty: < 500)
224.70 926.0 638 160-174
TRP (nl 85-98%) 65-77 75 57 50-60
Creatinine clearance
(nl 89-165 ml/min/1.73 m2)
92.8 99.8 107 112.7
β2-microglobulin
(nl < 0.03-0.37 mg/24 h)
81.6 nd nd nd
Protein excretion
(nl < 0.150 g/24 h)
1.86 3.21 2.1 2.0-3.0
Calcium excretion
(nl < 4 mg/kg/24 h)
10.1 10.9 8.9 6.7-7.2
  1. ALP: alkaline phosphatase; iPTH intact parathyroid hormone; nd: not determined; nl: normal level